The report provides a snapshot of the global therapeutic landscape for Growth Hormone Secretagogue Receptor Type 1 (GHS-R or GH-Releasing Peptide Receptor or GHRP or Ghrelin Receptor or GHSR)
The report reviews Growth Hormone Secretagogue Receptor Type 1 (GHS-R or GH-Releasing Peptide Receptor or GHRP or Ghrelin Receptor or GHSR) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
21), (22) The amino acid L-arginine--and other amino acids used in combination--promote GHRH-stimulated GH release, (23) and amino acids have been used as secretagogues in several dietary supplements, but their effects may not be as potent or predictable as the use of a GHRP, such as GHRP-2.
A deficiency of GHRP peptides is one of several factors that have been implicated in the reduction of GH secretion that has been documented in elderly individuals.
23) Furthermore, the administration of GHRP-2 in combination with GHRP or L-arginine can result in substantial increases in GH levels.
It is noted that GHRPs have greater GH-releasing actions than GHRP, and GHRP-2 can be administered by oral or intranasal routes with evidence of GH-releasing actions of a significant magnitude.
On the actions of the growth hormone-releasing hexapeptide, GHRP.
GH responses to GHRP and to GHRH in GH deficient children.